Dr Danielle Bond
Post-Doctoral Research Scientist
School of Biomedical Sciences and Pharmacy
- Email:danielle.bond@newcastle.edu.au
- Phone:40420872
Career Summary
Biography
Dr Bond is an Early Career Research Associate in the School of Biomedical Sciences and Pharmacy. She is based at the Central Coast campus of the University of Newcastle, working within the cancer research hub at Ourimbah in association with the Hunter Cancer Research Alliance (HCRA) and HMRI. She uses cutting-edge technology to test novel synthetic and natural products for the treatment of pancreatic cancer, as part of the Pancreatic Cancer Research Group, and is identifying blood markers in prostate cancer patients to help predict patient prognosis to current and new cancer treatments.
Dr Bond is primarily interested in pancreatic cancer as it has a very low survival rate and prostate cancer due to its high incidence rate among Australian men. She completed her PhD in Medical Biochemistry, which focused on breast and prostate cancers at the University of Newcastle in 2015. Since 2015, Dr Bond has been testing novel, natural and synthetic compounds as anti-pancreatic cancer agents and has been investigating blood markers for prostate cancer.
She has presented her work at both national and international conferences and continues to publish her findings, has helped organise local scientific meetings and has been an RHD representative for the school research committee. Dr Bond has received pilot grant funding through the Faculty of Health at the University of Newcastle and project funding from HMRI.
Qualifications
- Doctor of Philosophy, University of Newcastle
- Bachelor of Biomedical Sciences, University of Newcastle
- Bachelor of Biomedical Sciences (Hons), University of Newcastle
Keywords
- Breast Cancer
- Drug Discovery
- Pancreatic Cancer
- Prostate Cancer
- Tetraspanins
- micro-RNA
Languages
- English (Mother)
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 111201 | Cancer Cell Biology | 80 |
| 111204 | Cancer Therapy (excl. Chemotherapy and Radiation Therapy) | 20 |
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Post-Doctoral Research Scientist | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 6/04/2015 - 31/12/2016 | Research Associate | Faculty of Science and Information Technology, The University of Newcastle | Australia Environmental and Life Sciences Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (13 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 |
Predebon MJ, Bond DR, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'The bispidinone derivative 3,7-Bis-[2-(S)-amino-3-(1H-indol-3-yl)-propionyl]-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one dihydrochloride induces an apoptosis-mediated cytotoxic effect on pancreatic cancer cells in vitro', Molecules, 24 (2019) [C1] © 2019 by the authors. Pancreatic cancer (PC) is a complex, heterogeneous disease with a dismal prognosis. Current therapies have failed to improve survival outcomes, urging the n... [more] © 2019 by the authors. Pancreatic cancer (PC) is a complex, heterogeneous disease with a dismal prognosis. Current therapies have failed to improve survival outcomes, urging the need for discovery of novel targeted treatments. Bispidinone derivatives have yet to be investigated as cytotoxic agents against PC cells. The cytotoxic effect of four bispidinone derivatives (BisP1: 1,5-diphenyl-3,7-bis(2-hydroxyethyl)-3,7-diazabicyclo[3.3.1]nonan-9-one; BisP2: 3,7-bis-(2-(S)-amino-4-methylsulfanylbutyryl)-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one dihydrochloride; BisP3: [2-{7-[2-(S)-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyl]-9-oxo-1,5-diphenyl-3,7-diazabicyclo[3.3.1]non-3-yl}-1-(S)-(1H-indol-3-ylmethyl)-2-oxoethyl]-carbamic acid tertbutyl ester; BisP4: 3,7-bis-[2-(S)-amino-3-(1H-indol-3-yl)-propionyl]-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one dihydrochloride) was assessed against PC cell lines (MiaPaca-2, CFPAC-1 and BxPC-3). Cell viability was assessed using a Cell Counting Kit-8 (CCK-8) colorimetric assay, while apoptotic cell death was confirmed using fluorescence microscopy and flow cytometry. Initial viability screening revealed significant cytotoxic activity from BisP4 treatment (1 µM¿100 µM) on all three cell lines, with IC50 values for MiaPaca-2, BxPC-3, and CFPAC-1 16.9 µM, 23.7 µM, and 36.3 µM, respectively. Cytotoxic treatment time-response (4 h, 24 h, and 48 h) revealed a 24 h treatment time was sufficient to produce a cytotoxic effect on all cell lines. Light microscopy evaluation (DAPI staining) of BisP4 treated MiaPaca-2 PC cells revealed dose-dependent characteristic apoptotic morphological changes. In addition, flow cytometry confirmed BisP4 induced apoptotic cell death induction of activated caspase-3/-7. The bispidinone derivative BisP4 induced an apoptosis-mediated cytotoxic effect on MiaPaca-2 cell lines and significant cytotoxicity on CFPAC-1 and BxPC-3 cell lines. Further investigations into the precise cellular mechanisms of action of this class of compounds are necessary for potential development into pre-clinical trials.
|
||||||||||
| 2018 |
Brzozowski JS, Jankowski H, Bond DR, McCague SB, Munro BR, Predebon MJ, et al., 'Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines.', Lipids Health Dis, 17 211 (2018) [C1]
|
||||||||||
| 2018 |
Brzozowski JS, Bond DR, Jankowski H, Goldie BJ, Burchell R, Naudin C, et al., 'Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion', Scientific Reports, 8 1-13 (2018) [C1]
|
||||||||||
| 2018 |
Bond DR, Naudin C, Carroll AP, Goldie BJ, Brzozowski JS, Jankowski HM, et al., 'miR-518f-5p decreases tetraspanin CD9 protein levels and differentially affects non-tumourigenic prostate and prostate cancer cell migration and adhesion', ONCOTARGET, 9 1980-1991 (2018) [C1]
|
||||||||||
| 2018 |
Goldsmith CD, Bond D, Jankowski H, Weidenhofer JC, Stathopoulos C, Roach PD, Scarlett CJ, 'The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells', International Journal of Molecular Sciences, 19 (2018) [C1]
|
||||||||||
| 2018 |
Hong NTP, Sakoff JA, Bond DR, Quan VV, Bowyer MC, Scarlett CJ, 'In vitro antibacterial and anticancer properties of Helicteres hirsuta Lour. leaf and stem extracts and their fractions', MOLECULAR BIOLOGY REPORTS, 45 2125-2133 (2018) [C1]
|
||||||||||
| 2018 |
Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, Bowyer MC, Scarlett CJ, 'Eucalyptus microcorys leaf extract derived HPLC-fraction reduces the viability of MIA PaCa-2 cells by inducing apoptosis and arresting cell cycle', Biomedicine and Pharmacotherapy, 105 449-460 (2018) [C1]
|
||||||||||
| 2017 |
Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, et al., 'In vitro anticancer properties of selected Eucalyptus species', IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 53 604-615 (2017) [C1]
|
||||||||||
| 2017 |
Bhuyan DJ, Vuong QV, Bond DR, Chalmers AC, van Altena IA, Bowyer MC, Scarlett CJ, 'Exploring the Least Studied Australian Eucalypt Genera: Corymbia and Angophora for Phytochemicals with Anticancer Activity against Pancreatic Malignancies', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
|
||||||||||
| 2017 |
Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
|
||||||||||
| 2016 |
Weidenhofer JC, Colvin EK, Bond DR, Scarlett CJ, 'Animal models of pancreatic cancer and their application in clinical research', Gastrointestinal Cancer : Targets and Therapy, 2016 31-39 (2016) [C1]
|
||||||||||
| 2014 |
Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1] © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechan... [more] © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, t<inf>B</inf> = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.
|
||||||||||
| 2014 |
Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
|
||||||||||
| Show 10 more journal articles | |||||||||||
Conference (16 outputs)
| Year | Citation | Altmetrics | Link | |||||
|---|---|---|---|---|---|---|---|---|
| 2017 |
Bond D, Phuong TT, Do TH, Nguyen MK, Weidenhofer J, Scarlett CJ, 'Vietnamese medicinal plant compounds show potent anti-pancreatic cancer activity in vitro', CANCER RESEARCH, Washington, DC (2017)
|
|||||||
| 2017 |
Goldsmith CD, Jankowski H, Bond D, Weidenhofer J, Stathopoulos C, Roach P, Scarlett C, 'The olive biophenol oleuropein selectively induces apoptosis in pancreatic cancer cells in vitro', CANCER RESEARCH, Washington, DC (2017)
|
|||||||
| 2016 |
Goldsmith C, Bond D, Stathopoulos C, Roach P, Scarlett C, 'THE OLIVE PHENOLIC COMPOUNDS APIGENIN, LUTEOLIN AND OLEUROPEIN INDUCE CELL-CYCLE ARREST AND APOPTOSIS IN PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
|
|||||||
| 2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding KA, Weidenhofer J, 'Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers', Boston, MA (2015) [O1]
|
|||||||
| 2015 |
Brzozowski J, Coldie B, Jankowski H, Bond D, Scarlett C, Dun M, et al., 'THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding K, Weidenhofer J, 'PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Bond D, Turner A, Richmond R, Sadeqzadeh E, Vuong Q, Bhuyan D, et al., 'THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2015 |
Predebon M, Bond D, Brzozowski J, Jankowski H, Deane F, Tarleton M, et al., 'A BISPIDINONE ANALOGUE INDUCES AN APOPTOSIS-MEDIATED CYTOTOXIC EFFECT ON PANCREATIC CANCER CELLS IN VITRO', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2014 |
Bond DR, Passfield C, Cairns M, Ashman LK, Weidenhofer J, 'Posttranscriptional regulation of tetraspanins CD151 & CD9 in breast & prostate cancers', CANCER RESEARCH, San Diego, CA (2014) [E3]
|
|||||||
| 2013 |
Weidenhofer J, Bond D, Copeland B, Ashman L, 'Tetraspanin protein turnover rates vary in prostate cancer cell lines', BJU INTERNATIONAL (2013) [E3]
|
|||||||
| 2013 |
Bond D, Cairns M, Ashman L, Weidenhofer J, 'Post-transcriptional regulation of CD151 & CD9 by miRNAs in prostate cancer', BJU INTERNATIONAL (2013) [E3]
|
|||||||
| 2012 |
Bond DR, Cairns MJ, Ashman LK, Weidenhofer JC, 'Investigating micro-RNA regulation of tetraspanins CD151 and CD9 in prostate cancer', Febs Journal, Seville, Spain (2012) [E3]
|
|||||||
| Show 13 more conferences | ||||||||
Grants and Funding
Summary
| Number of grants | 3 |
|---|---|
| Total funding | $425,000 |
Click on a grant title below to expand the full details for that specific grant.
20181 grants / $20,000
Investigating the role of stromal heterogeneity in Myelodysplastic Syndrome following Azacitadine therapy $20,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Danielle Bond, Doctor Heather Lee, Doctor Anoop Enjeti |
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801353 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
20141 grants / $400,000
Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000
Funding body: Construction, Forestry, Mining and Energy Union
| Funding body | Construction, Forestry, Mining and Energy Union |
|---|---|
| Project Team | Doctor Jude Weidenhofer, Doctor Kathryn Skelding, Doctor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond |
| Scheme | Research Funding |
| Role | Investigator |
| Funding Start | 2014 |
| Funding Finish | 2017 |
| GNo | G1400921 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
20111 grants / $5,000
Investigation of miRNA targeting of tetraspanins CD151 and CD9 in breast cancer $5,000
Funding body: The Faculty of Health, The University of Newcastle
| Funding body | The Faculty of Health, The University of Newcastle |
|---|---|
| Project Team | Judith Weidenhofer, Murray Cairns & Danielle Bond |
| Scheme | Faculty of Health Pilot Grant |
| Role | Investigator |
| Funding Start | 2011 |
| Funding Finish | 2011 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Research Supervision
Number of supervisions
Current Supervision
| Commenced | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2017 | PhD | Targeting Cancer-Initiating Cells with DNA Methyltransferase Inhibitors: Single-cell Analysis to Decipher Molecular Mechanisms and Improve Efficacy | PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
Dr Danielle Bond
Positions
Post-Doctoral Research Scientist
Cancer Epigenetics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Casual Lecturer
Cancer Epigenetics
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Contact Details
| danielle.bond@newcastle.edu.au | |
| Phone | 40420872 |
Office
| Room | Level 3 West |
|---|---|
| Building | HMRI |
| Location | HMRI , |
